Skip to main content

Table 1 CYP2D6 allele frequency at TS-141 Phase I study

From: Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder

CYP2D6 Phenotype

N

(%)

Allele

N

(%)

Total

42

(100.0)

   

PM

1

(2.4)

*5/*5

1

(2.4)

IM

5

(11.9)

*5/*10

1

(2.4)

*10/*10

3

(7.1)

*10/*41

1

(2.4)

EM

35

(83.3)

*1/*1

9

(21.4)

*1/*2

2

(4.8)

*1/*5

2

(4.8)

*1/*10

14

(33.3)

*1/*10A

2

(4.8)

*1/*41

2

(4.8)

*2/*10

4

(9.5)

UM

1

(2.4)

*1/*2A

1

(2.4)

  1. A Amplification